Molecular pathology of colorectal cancer

Polish Journal of Pathology

Volumn 65, Issue 4, 2014, Pages 257-266

  Bosman, Fred T ^a   Yan, Pu ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Chromosomal instability; Colorectal carcinoma; CpG island methylator phenotype (CIMP); KRAS; Microsatellite instability; Molecular pathology

Indexed keywords

CARCINOMA; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; HUMAN; LARGE INTESTINE; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; PATHOLOGY;

CARCINOMA; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; HUMANS; INTESTINE, LARGE; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84922011142     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/pjp.2014.48094     Document Type: Review

References (50)

1. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine Nat Rev Clin Oncol 2011; 8: 184-187.
2. Bosman FT. Colorectal cancer. In: World Cancer Report 2014 (Ed. Stewart BW and Wild CP). IARC Press, Lyon 2014; 32-402.
3. Fearon ER Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis 2011; 6: 479-507.
4. Sadanandam A, Lyssiotis CA, Homicsko K, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625.
5. De Sousa E Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19: 614-618.
6. Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231: 63-76.
7. Fearon ER, Vogelstein B. A genetic model for colorectal carcinogenesis. Cell 1996; 87: 159-170.
8. Hemminki A, Peltomäki P, Mecklin JP, et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 1994; 8: 405-410.
9. Jass JR. Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol 2005; 2: 398-405.
10. Briggs S, Tomlinson I. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013; 230: 148-153.
11. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237.
12. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and spoadic colon carcinomas. Lancet 1992; 340: 626-630.
13. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24.
14. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007; 61: 153-161.
15. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992; 1: 229-233.
16. Tian S, Simon I, Moreno V, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013; 62: 540-549.
17. Yan P, Saraga EP, Bouzourene H, et al. Telomerase activation in colorectal carcinogenesis. J Pathol 1999; 189: 207-212.
18. Fleming NI, Jorissen RN, Mouradov D, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Crit Rev Oncol Hematol 2011; 79: 1-16.
19. Nielsen M, Morreau H, Vasen HF, Hes FJ. MUTYH-associated polyposis (MAP). Cancer Res 2013; 73: 725-735.
20. Sampson JR, Jones N. MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol 2009; 23: 209-218.
21. Lynch HT, Lanspa SJ, Boman BM, et al. Hereditary nonpolyposis colorectal cancer – Lynch syndromes I and II. Gastroenterol Clin North Am 1988; 17: 679-712.
22. Nyström-Lahti M, Parsons R, Sistonen P, et al. Mismatch repair genes on chromosomes 2p and 3p account for a major share of hereditary nonpolyposis colorectal cancer families evaluable by linkage. Am J Hum Genet 1994; 55: 659-665.
23. Mead LJ, Jenkins MA, Young J, et al. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes. Clin Cancer Res. 2007; 13: 2865-2869.
24. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol 2009; 33: 1639-1645.
25. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58: 3455-3460.
26. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol 2011; 5: 385-399.
27. Tougeron D, Maby P, Elie N, et al. Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers. PLoS One 2013; 8: e61001.
28. Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev 2014; 24: 107-113.
29. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008; 268: 177-186.
30. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011; 42: 1-10.
31. Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013; 62: 367-386.
32. Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a ‚fusion' pathway to colorectal cancer. Histopathology 2006; 49: 121-131.
33. Sadanandam A, Wang X, de Sousa E Melo F, et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 2014; 13: 353-357.
34. Pox CP. Controversies in colorectal cancer screening. Digestion 2014; 89: 274-281.
35. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370: 1287-1297.
36. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol 2011; 38: 511-520.
37. Omberg L, Ellrott K, Yuan Y, et al. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet 2013; 45: 1121-1126.
38. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg 2013; 257: 1053-1058.
39. Reimers MS, Kuppen PJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst 2014; 106 pii: dju269. doi: 10.1093/jnci/dju269.
40. Di Narzo AF, Tejpar S, Rossi S, et al. Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. J Natl Cancer Inst 2014; 106 pii: dju247. doi: 10.1093/jnci/dju247.
41. Van Loon K, Venook AP. Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol 2011; 23: 403-409.
42. Yuan Y, Tan CW, Shen H, et al. Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks. Hepatogastroenterology 2012; 59: 2461-2465.
43. Jensen NF, Smith DH, Nygård SB, et al. Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scand J Gastroenterol 2012; 47: 340-355.
44. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
45. Peeters M, Douillard JY, Van Cutsem E, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013; 31: 759-765.
46. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
47. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, et al. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 2010; 5: 19-28.
48. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, et al. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol 2014; 8: 1084-1094.
49. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
50. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19: 1389-1400.